Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena, Takayuki Yoshino, Hisato Kawakami et al.|The Lancet Oncology|2021

Cited by 411